Palisade bio announces $2.5 million registered direct offering and concurrent private placement priced above market under nasdaq rules

Carlsbad, ca, dec. 30, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 1,052,631 shares of common stock (or certain pre-funded warrants in lieu thereof) in a registered direct offering and concurrent private placement, at a purchase price per common share of $2.375. certain investors will receive unregistered pre-funded warrants in the private placement in lieu of common stock, subject to beneficial ownership limitations. the company has also agreed to issue to the investors, in the private placement, unregistered warrants to purchase up to 1,052,631 shares of common stock (the “common warrants”). these common warrants will have a term of five (5) years and an exercise price of $2.375 per share. accordingly, the company entered into agreements to sell (i) an aggregate of 513,842 shares of registered common stock and pre-funded warrants to purchase common stock, (ii) pre-funded warrants that are not registered to purchase an aggregate of 538,789 shares of common stock, and (iii) 1,052,631 unregistered common warrants. the closing of the offering is expected to take place on or about january 4, 2022, subject to the satisfaction of customary closing conditions.
PALI Ratings Summary
PALI Quant Ranking